Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-033 SAD and Food Effect Study in Healthy Volunteers
NCT07013097Phase 1Recruiting
- Sponsor
- Prime Gene Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PG-033 in lichen simplex chronicus (LSC) (4 arms), sponsored by Prime Gene Therapeutics. Primary endpoint: Safety and tolerability of PG-033 tablets at 14 days. Started May 2025; status: recruiting.
02
Drugs
PG-033
03
Conditions
lichen simplex chronicus (LSC)
Beyond the preview
Go deeper on NCT07013097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013097.